JSF Financial LLC Acquires 114 Shares of United Therapeutics Co. (NASDAQ:UTHR)

JSF Financial LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,996 shares of the biotechnology company’s stock after purchasing an additional 114 shares during the quarter. JSF Financial LLC’s holdings in United Therapeutics were worth $1,057,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in UTHR. Cetera Investment Advisers lifted its position in shares of United Therapeutics by 8.7% in the 2nd quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock worth $1,964,000 after acquiring an additional 493 shares during the period. SG Americas Securities LLC lifted its position in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock worth $535,000 after acquiring an additional 594 shares during the period. CWM LLC lifted its position in shares of United Therapeutics by 108.3% in the 3rd quarter. CWM LLC now owns 4,006 shares of the biotechnology company’s stock worth $1,436,000 after acquiring an additional 2,083 shares during the period. Ritholtz Wealth Management lifted its position in shares of United Therapeutics by 14.3% in the 3rd quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 105 shares during the period. Finally, CHICAGO TRUST Co NA bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $204,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $345.64 on Tuesday. The firm has a market capitalization of $15.43 billion, a price-to-earnings ratio of 15.18, a PEG ratio of 0.92 and a beta of 0.57. The business’s fifty day moving average price is $362.37 and its two-hundred day moving average price is $358.13. United Therapeutics Co. has a 52 week low of $210.64 and a 52 week high of $417.82.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. TD Cowen raised their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $382.08.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $911,330.28. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,864 shares of company stock worth $41,036,365 in the last three months. Insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.